Shamik J. Parikh Buys 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) insider Shamik J. Parikh purchased 7,500 shares of the company’s stock in a transaction that occurred on Thursday, April 10th. The stock was acquired at an average cost of $1.55 per share, with a total value of $11,625.00. Following the purchase, the insider now directly owns 7,500 shares of the company’s stock, valued at $11,625. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $1.55 on Thursday. The company has a 50 day simple moving average of $2.71 and a two-hundred day simple moving average of $4.10. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.97. The company has a market capitalization of $240.43 million, a price-to-earnings ratio of -1.16 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. On average, analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HUMA has been the subject of several research analyst reports. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humacyte presently has an average rating of “Buy” and a consensus target price of $13.71.

Hedge Funds Weigh In On Humacyte

Large investors have recently modified their holdings of the stock. Endowment Wealth Management Inc. grew its position in Humacyte by 3.6% during the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after purchasing an additional 3,590 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Humacyte by 18.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after buying an additional 4,327 shares during the last quarter. Beacon Pointe Advisors LLC increased its position in shares of Humacyte by 33.3% during the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after acquiring an additional 5,000 shares in the last quarter. Rhumbline Advisers increased its position in shares of Humacyte by 4.6% during the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after acquiring an additional 5,005 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Humacyte by 25.3% in the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock worth $132,000 after acquiring an additional 5,293 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.